Sulfamethoxazole is a synthetic antibiotic belonging to the sulfonamide class, widely used in combination with trimethoprim to treat various bacterial infections. This combination is commonly known as co-trimoxazole.
Sulfamethoxazole inhibits the bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA), thereby preventing the growth and proliferation of bacteria.
Sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial folate synthesis [3.].
It is in the Sulfonamide Antibiotic, Folic Acid Antagonist, and Sulfonamide Combination drug class [1.].
It is often combined with trimethoprim for synergistic effects and to reduce resistance development [3.].
Trimethoprim-sulfamethoxazole (TMP/SMX), also known as co-trimoxazole or by the brand name Bactrim, is a combination antibiotic that has played a significant role in treating various infections for over three decades [7.].
Despite the introduction of newer antibiotics, sulfonamides remain relevant, particularly for treating Pneumocystis jirovecii pneumonia in AIDS patients [5.].
The emergence of resistance threatens the continued use of sulfonamides, prompting the development of new generations of compounds to overcome resistance mechanisms [2.].
Sulfamethoxazole's mechanism of action involves inhibiting tetrahydrobiopterin biosynthesis. This mechanism of action may explain some central nervous system side effects [4.].
Sulfonamides are structural analogs of para-aminobenzoic acid (PABA) and inhibit the enzyme dihydropteroate synthase (DHPS), crucial for folic acid synthesis. This inhibition prevents bacterial DNA synthesis. [5.].
When combined with diaminopyrimidines like trimethoprim, which inhibits dihydrofolate reductase, the combination (e.g., sulfamethoxazole/trimethoprim) results in a synergistic antibacterial effect [5.].
Sulfamethoxazole is used in combination with trimethoprim (SMX/TMP) for various bacterial infections.
Common uses include:
Common adverse reactions include gastrointestinal intolerance and skin eruptions, with rare hematologic reactions [3.].
Adverse effects of sulfonamides can include:
Potential drug interactions including displacement of warfarin, phenytoin, bilirubin may occur.
Bacterial resistance to sulfonamides can be chromosomal or plasmid-mediated. Common mechanisms include mutations in DHPS that reduce drug binding or overproduction of PABA. [5.].
Resistance genes such as Sul1, Sul2, Sul3, and Sul4 encode altered enzymes with reduced sulfonamide affinity. Cross-resistance among sulfonamides is typical, and resistance to one often implies resistance to all [5.].
Sulfonamides can displace warfarin from its plasma protein-binding sites, leading to increased levels of free warfarin in the bloodstream.
Warfarin is a potent anticoagulant, and its displacement can result in enhanced anticoagulant effects, increasing the risk of bleeding.
Patients on both sulfonamides and warfarin may require careful monitoring of their International Normalized Ratio (INR) and potential dose adjustments of warfarin to maintain safe and effective anticoagulation.
Phenytoin is an anticonvulsant that is highly protein-bound in the plasma. Sulfonamides can displace phenytoin from its binding sites, increasing the concentration of free phenytoin.
This can lead to toxicity, presenting as sedation, nystagmus, ataxia, and other central nervous system effects.
Monitoring phenytoin levels and adjusting the dose may be necessary when initiating or discontinuing sulfonamide therapy.
In neonates, sulfonamides can displace bilirubin from albumin-binding sites.
Free bilirubin can cross the blood-brain barrier and cause kernicterus, a type of brain damage resulting from high levels of unconjugated bilirubin. Due to this risk, sulfonamides are generally contraindicated in late pregnancy and in newborns.
Antacids can interfere with the absorption of sulfonamides when co-administered orally.
The presence of antacids in the gastrointestinal tract can reduce the bioavailability of sulfonamides, diminishing their therapeutic efficacy. Patients should be advised to take sulfonamides and antacids at different times to avoid this interaction.
Sulfonamide solutions are incompatible with calcium-containing fluids when administered intravenously.
Mixing these can lead to precipitation, reducing the effectiveness of the sulfonamide and potentially causing harm. It is essential to use appropriate IV fluids and avoid combining sulfonamides with calcium-containing solutions.
Prolonged use of sulfonamides may lead to detectable changes in these parameters due to liver and kidney interactions.
Decreased platelet, RBC, and WBC counts can occur with regular sulfonamide use, necessitating regular blood count monitoring.
Changes in urine color, presence of sulfonamide crystals, and increased porphyrins and urobilinogen can be seen.
Sulfamethoxazole monitoring is only indicated when prolonged (>3 months) therapy is required [6.].
Sulfamethoxazole levels in blood may be assessed for monitoring therapeutic efficacy, ensuring patient safety, and avoiding drug resistance.
Sample collection requires a venipuncture. Patients should consult with the ordering provider prior to sample collection to ensure proper timing of sample collection. Monitoring collection times are given as 1 hour after IV administration or 2-3 hours after oral administration [6.].
Liquid-Chromatography Mass Spectrometry (LC-MS/MS) is the method often used.
One laboratory recommends levels of >50 mcg/mL (Peak) [6.]
Levels above this range may indicate potential toxicity, requiring dose adjustment or additional medical intervention.
Symptoms of sulfamethoxazole toxicity, such as nausea, vomiting, or renal impairment, should prompt an immediate review of the patient’s drug levels.
Conversely, levels below the therapeutic range may suggest inadequate dosing, poor patient compliance, or drug interactions that reduce the drug’s bioavailability.
Subtherapeutic levels necessitate a review of the treatment regimen to ensure effective bacterial eradication and prevent the development of drug resistance.
Sulfamethoxazole is an antibiotic commonly used to treat a variety of bacterial infections. This FAQ section addresses common questions about sulfamethoxazole, its uses, side effects, dosage, and related considerations.
Sulfamethoxazole is an antibiotic that belongs to the class of sulfonamides. It is often used in combination with trimethoprim to treat bacterial infections by inhibiting the production of folic acid in bacteria, which is essential for their growth and replication.
Sulfamethoxazole is used to treat a wide range of bacterial infections, including urinary tract infections (UTIs), bronchitis, ear infections, traveler's diarrhea, and certain types of pneumonia.
When combined with trimethoprim, it is commonly referred to as co-trimoxazole or by the brand name Bactrim.
Common side effects of sulfamethoxazole include nausea, vomiting, loss of appetite, and skin rash. More serious side effects can include severe allergic reactions, liver damage, blood disorders, and kidney problems.
It is important to contact a healthcare provider if any severe or unusual symptoms occur.
The combination of sulfamethoxazole and trimethoprim is commonly sold under the brand name Bactrim, as well as Septra and Cotrim.
The dosage of sulfamethoxazole varies depending on the type and severity of the infection being treated. It is typically taken in combination with trimethoprim. For adults, the standard dose for most infections is one or two tablets every 12 hours.
It is essential to follow the prescribed dosage and complete the full course of treatment.
When taking sulfamethoxazole/trimethoprim, it is advisable to avoid alcohol which can interfere with the medication's effectiveness or increase the risk of side effects.
Individuals taking other medications along with these antibiotics should consult the prescribing provider for any additional interactions.
Sulfamethoxazole works by inhibiting the production of folic acid in bacteria, which is necessary for their growth and replication.
By stopping the production of this essential nutrient, the antibiotic effectively kills the bacteria or stops their growth, helping to clear the infection.
[1.] DynaMedex. Dynamedex.com. Published 2024. Accessed August 7, 2024. https://www.dynamedex.com/drug-monograph/sulfamethoxazole-trimethoprim
[2.] Estrada A, Wright DL, Anderson AC. Antibacterial Antifolates: From Development through Resistance to the Next Generation. Cold Spring Harbor Perspectives in Medicine. 2016;6(8). doi:https://doi.org/10.1101/cshperspect.a028324
[3.] Gleckman R, Alvarez S, Joubert DW. Drug therapy reviews: Trimethoprim-sulfamethoxazole. American Journal of Health-System Pharmacy. 1979;36(7):893-906. doi:https://doi.org/10.1093/ajhp/36.7.893
[4.] Haruki H, Pedersen MG, Gorska KI, Pojer F, Johnsson K. Tetrahydrobiopterin Biosynthesis as an Off-Target of Sulfa Drugs. Science. 2013;340(6135):987-991. doi:https://doi.org/10.1126/science.1232972
[5.] Hassanein MM. Sulfonamides: far from obsolete. International Journal of Contemporary Pediatrics. 2019;6(6):2740. doi:https://doi.org/10.18203/2349-3291.ijcp20194768
[6.] SFZ - Overview: Sulfamethoxazole, Serum. www.mayocliniclabs.com. https://www.mayocliniclabs.com/test-catalog/Overview/8238
[7.] Wormser GP, Keusch GT. Trimethoprim/Sulfamethoxazole: An Overview. Handbook of experimental pharmacology. Published online January 1, 1983:1-8. doi:https://doi.org/10.1007/978-3-642-81890-5_1